

.
 (. 9.4).
 /nW
 (. 98).
 : 10%
 (; > ! ()
 (. pH
 ,
 ,
 , 0,5 / , 30-60 .
 — 0,25 / , —
 0,1 / / / / - 10 -20 .
 5-10
 <<-... « <| (-
 . : MmiiiH
 ! (.
 10 (1
 2-8° ,
 5-10%.
 14
 ! ! ; ,
 --
 ,
 ; 0,5 /

9.8. ,

(,)'		
()		
-		
()		
()		
(Myasthenia gravis)	II	
(,)		
(,)		

• 0,5 /

• - - - - -

• - - - - -

• ()

• - - - - -

• ;

2-3
0,08-0,12 /

0,01 / - 0,04 / ,
20-40 .

1 1-2
2-8° , 6

20%

()

()

(25%).

(20%). (70%)

3-

0,12 / .

— 0,01 / — 0,04 / ,

1-2 / / 15-20

30% , ,

() .

10 5 10) .

24 , (0,4 /), 25

5-12 / / 1 /

2 / ;

(0,28 /) 3-6 (,

) . /

0,15 / .

0,08-

0,45-

- Feldman S: *Neuromuscular Blockade*. Butterworth-Heinemann, 1996.
- ?
- Haywood PT, Divekar N, Karalliedde LD: Concurrent medication and the neuromuscular junction. *Eur J Anaesthesiol* 1999; 16:77.
- Kopman AF, Yee PS, and Neuman GG: Relationship of train-of-four fade to clinical signs and symptoms of residual paralysis in awake volunteers. *Anesthesiology* 1997;86:765.
- Kopman AF, Klewicka MM, Koman DJ: Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. *Anesthesiology* 1999;90:425.
- Lee C: Structure, conformation, and action of neuromuscular blocking drugs. *Br J Anaesth* 2001;87:755.
- Moore EW, Hunter JM: The new neuromuscular blocking agents: Do they offer any advantages? *Br J Anaesth* 2001;87:912.
- Naguib M, Flood P, McArdle JJ, Brenner HR: Advances in the neurobiology of the neuromuscular junction. *Anesthesiology* 2002;96:202.
- Naguib M, Samarkandi A, Riad W, Alharby SW: Optimal dose of succinylcholine revisited. *Anesthesiology* 2003;99:1045.
- Schow AJ, Libarsky DA, Olson RP: Can succinylcholine be used safely in hyperkalemic patients? *Anesth Analg* 2002;95:119.
- Berg , Viby-Morgensen J, Chraemmer Jorgensen , et al: Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium, and pancuronium. *Acta Anaesthesiol Scand* 1997;41:1095.
- Caldwell JE: The problem with long-acting muscle relaxants? They cost more! [Editorial] *Anesth Analg* 1997;85:473.
- Donati F: The right dose of succinylcholine. *Anesthesiology* 2003;99:1037.
- ?

() (: - - -) - - -

5 100 - - -

() , - - -

() , - - -

), (: - - -

(.10.2).) - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

, - - -

(). , , - - -

,

(.10.1). - - -

10.2.

TOF- ; 6).
 ()
 TOF- , - ,
 (,
 10
 TOF- ,
 ()— 40 .
 , ,
 ;
 ;
 ;
 (, -)
 () .
 (25-50%)
 (50-75%).

TOF- ; 6).
 ()
 TOF- , - ,
 (,
 10
 TOF- ,
 ()— 40 .
 , ,
 ;
 ;
 ;
 (, -)
 () .
 10%)
 (, -)